Mineralys Therapeutics, Inc.

    • Market Cap $634.92M
    • PE -4
    • Debt $NaN
    • Cash $97.27M
    • EV $NaN
    • FCF $NaN

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$153.25M
    EBIT-$168.35M
    ROE-65%
    ROA-63%
    Equity$236.93M
    Growth Stability1
    PE-4.14
    PB2.68
    Price/Cash0.15
    Equity CAGR-5%
    Earnings Growth YoY148%
    Earnings Growth QoQ37%
    Equity CAGR 5Y-5%
    Equity CAGR 3Y-5%
    Market Cap$634.92M
    Assets$268.25M
    Cash$97.27M
    Shares Outstanding48.06M
    Working Capital236.41M
    Current Ratio8.55
    Shares Growth 3y42%
    Equity Growth QoQ-18%
    Equity Growth YoY-10%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

    SEC Filings

    Direct access to Mineralys Therapeutics, Inc. (MLYS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31

    Sector Comparison

    How does Mineralys Therapeutics, Inc. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Mineralys Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Mineralys Therapeutics, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Mineralys Therapeutics, Inc..

    0
    012345678910TV
    fcf$0$0$0$0$0$0$0$0$0$0$0$0
    DCF$0$0$0$0$0$0$0$0$0$0$0
    Value$0

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/202212/2023TTM
    Net Margins---
    ROA--34%-63%
    ROE--30%-65%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/202212/2023TTM
    Debt over FCF---
    Debt over Equity---
    Growth Stability--1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/202212/2023CAGR 5Y
    Revenue YoY growth---
    Earnings YoY growth-141%-
    Equity YoY growth--561%-5%
    FCF YoY growth---